Abstract:
Liver cancer is one of the most common malignant cancers worldwide. The poor response of liver cancer
to chemotherapy has whipped up the interest in targeted therapy with monoclonal antibodies because
of its potential efficiency. One promising target is cluster of differentiation 24 (CD24), which is known
to beover-expressed on hepatocellular carcinoma (HCC), providing prospect for HCC targeted diagnosis
and therapy. In this study we developed a novel CD24 targeted monoclonal antibody G7mAb based on
hybridoma technology and then generated a single-chain antibodyfragment (scFv) G7S. Firstly, ELISA,
western blot, and flow cytometry assays demonstrated specific binding of CD24 by G7mAb and G7S. Further,
G7mAb was demonstrated to have similar binding capacity as ML5 (a commercial Anti-CD24 Mouse
Antibody) inimmunohistochemical assay. Further more, a near-infrared fluorescent dye multiplex probe
amplification (MPA) was conjugated to G7mAb and G7S to form G7mAb-MPA and G7S-MPA. The nearinfrared
fluorescence imaging revealed that G7mAb and G7S aggregate in CD24 + Huh7 hepatocellular
carcinoma xenograft tissuevia specific binding to CD24 in vivo. In conclussion, G7mAb and G7S were
tumor targeted therapeutic and diagnostic potentials in vitro and in vivo as anticipated.
